Prime Medicine Has Begun Clinical Trial for Wilson Disease
The study evaluates an investigational Prime Editor designed to correct the genetic cause of Wilson disease.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Should the federal government increase support for research into rare genetic diseases?
Prime Medicine has dosed the first patient in a Phase 1/2 clinical trial for PM577a, an investigational in vivo Prime Editor targeting the H1069Q mutation associated with Wilson disease. The FDA has also granted the candidate Rare Pediatric Disease designation.
Why it matters
The study aims to address Wilson disease, a genetic disorder of hepatic copper transport, by correcting the underlying H1069Q mutation in the ATP7B gene. This clinical milestone marks the transition of Prime Editor technology from laboratory research to human testing.
PM577a utilizes a Prime Editor—a gene-editing tool that acts like a word processor to correct specific DNA sequences—to target the H1069Q mutation in the ATP7B gene. The trial evaluates safety and efficacy in adults and adolescents receiving the therapy as a single intravenous infusion.
The players
Prime Medicine
A biotechnology company focused on developing gene-editing therapies using Prime Editor technology to correct disease-causing genetic mutations.
U.S. Food and Drug Administration
The federal agency responsible for regulating medical products and providing formal designations for therapies targeting rare pediatric conditions.
The details
Wilson disease is caused by mutations in the ATP7B gene, which impairs the liver's ability to properly transport copper, leading to toxic accumulation in organs. PM577a is designed to directly correct the H1069Q mutation at its source rather than treating the metabolic symptoms. This first-in-human study uses an open-label design, where both researchers and participants are aware of the treatment being administered, to track the biological response to escalating doses.
Timeline
October 5, 2026: Prime Medicine announced the first patient dosing.
2027: Initial clinical trial data is expected.
The Tech Race
This clinical entry represents a significant milestone for the development of Prime Editor gene-editing technology. It places the firm in the nascent field of in vivo genetic correction, competing with established CRISPR-based modalities that are currently moving through similar regulatory phases.
The clinical trial is currently enrolling participants who carry the H1069Q mutation. Initial efficacy and safety data are not expected until 2027, and the therapy is currently an investigational candidate not available for clinical use.
The takeaway
The successful dosing of the first patient signals that Prime Editor technology has reached the clinical testing phase. Observers should track the 2027 data readout, which will serve as a primary indicator of whether this method can effectively correct hepatic copper transport at scale.
Further reading
For more developments in genetic medicine, visit the Biotech section.
More information
View the complete clinical trial information page for protocol details.
Live Poll
Should the federal government increase support for research into rare genetic diseases?
